SCHEMBL755347

SCHEMBL755347

CC(=O)OCCOCc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.69
TSHR P16473 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 2/20 0.47
TDP1 Q9NUW8 4/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
MAPK1 P28482 2/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A3 Q01959 1/20 0.47
KMT2A Q03164 1/20 0.47
HTT P42858 1/20 0.46
MAOB P27338 1/20 0.45
CYP3A4 P08684 1/20 0.44
NAAA Q02083 1/20 0.44
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17459104 0.98 ALDH1A1 (0.67) ALDH1A1TSHRSMN1; SMN2LMNATDP1
SCHEMBL28461120 0.93 ALDH1A1 (0.61) ALDH1A1TSHRSMN1; SMN2LMNATDP1
SCHEMBL9192089 0.89 ALDH1A1 (0.65) ALDH1A1TSHRSMN1; SMN2LMNATDP1
SCHEMBL13316186 0.85 ALDH1A1 (0.48) ALDH1A1TSHRSMN1; SMN2TDP1SLC6A2
SCHEMBL17459122 0.85 ALDH1A1 (0.58) ALDH1A1TSHRSMN1; SMN2LMNATDP1
SCHEMBL8506264 0.85 TSHR (0.54) ALDH1A1TSHRSMN1; SMN2LMNATDP1
SCHEMBL3543222 0.83 LMNA (0.53) ALDH1A1TSHRSMN1; SMN2LMNATDP1
SCHEMBL7185515 0.83 ALDH1A1 (0.71) ALDH1A1TSHRSMN1; SMN2LMNATDP1
SCHEMBL3543227 0.83 LMNA (0.53) ALDH1A1TSHRSMN1; SMN2LMNATDP1
SCHEMBL316845 0.83 THRB (0.54) ALDH1A1TSHRSMN1; SMN2LMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112823792-B Sustained release microsphere of galanthamine pamoate for injection and preparation method thereof 鲁南制药集团股份有限公司 2023-07-14 CN claimed
CN-109563363-B Formulation and process for producing highly conductive copper patterns 铜打印科技有限公司 2023-03-10 CN claimed
CN-112823792-A Galanthamine pamoate sustained-release microspheres for injection and preparation method thereof 鲁南制药集团股份有限公司 2021-05-21 CN claimed
EP-3494184-A1 FORMULATIONS AND PROCESSES FOR PRODUCING HIGHLY CONDUCTIVE COPPER PATTERNS Copprint Technologies Ltd (IL) 2019-06-12 EP claimed
WO-2018025271-A1 FORMULATIONS AND PROCESSES FOR PRODUCING HIGHLY CONDUCTIVE COPPER PATTERNS COPPRINT TECHNOLOGIES LTD (IL) 2018-02-08 WO claimed
US-4665067-A BACTERICIDES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1987-05-12 US claimed
EP-4722293-A1 METHOD FOR PRODUCING HIGHLY CONDUCTIVE COMPOSITION AFTER DRYING AND FIRING Tatsuta Electric Wire & Cable Co., Ltd. (JP) 2026-04-08 EP disclosed
WO-2025233842-A1 METHOD FOR PRODUCING CONDUCTIVE FILM, ELECTROMAGNETIC WAVE SHIELDING LAYER, ELECTRODE PATTERN, AND SINTERING DEVICE RICOH COMPANY, LTD. (JP) 2025-11-13 WO disclosed
WO-2025045145-A1 WRN HELICASE-INHIBITING BIS-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF 广州科恩泰生物医药科技有限公司 2025-03-06 WO disclosed
WO-2025023272-A1 METHOD FOR PRODUCING HIGHLY CONDUCTIVE COMPOSITION AFTER DRYING AND FIRING タツタ電線株式会社 2025-01-30 WO disclosed
CN-119274843-A Copper paste and method for producing copper paste 常州聚和新材料股份有限公司 2025-01-07 CN disclosed
US-20240327668-A1 FORMULATIONS AND PROCESSES FOR PRODUCING HIGHLY CONDUCTIVE COPPER PATTERNS COPPRINT TECHNOLOGIES LTD (IL) 2024-10-03 US disclosed
US-11958783-B2 Composition, film, and method for producing film SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2024-04-16 US disclosed
US-7781443-B2 cholesteryl ester transfer protein (CETP) anatgonists such as 2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester, having improved bioavailability MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-08-24 US disclosed
EP-2181985-A1 Antiviral Agent SHIONOGI & CO., LTD. (JP) 2010-05-05 EP disclosed
US-7217424-B2 Compositions containing esters of aromatic alkoxylated alcohols and fatty carboxylic acids CRODA, INC. (US) 2007-05-15 US disclosed
US-20070032485-A1 Tetrahydronaphthyridine derivatives and a process for preparing the same TANABE SEIYAKU CO., LTD. 2007-02-08 US disclosed
WO-2005010011-A2 METHODS OF SYNTHESIS OF ACYLOXYALKYL COMPOUNDS XENOPORT, INC. (US) 2005-02-03 WO disclosed
US-20040229909-A1 Antiviral agent SHIONOGI & CO., LTD. (JP) 2004-11-18 US disclosed
EP-1422218-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2004-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229909-A1 Antiviral agent ZC3HAV1, ZC3HAV1L, DUT ALDH1A1 658/4885TSHR 4237/4885SMN1; SMN2 3953/4885
US-20070032485-A1 Tetrahydronaphthyridine derivatives and a process for preparing the same CETP, MTTP, NPC1L1 ALDH1A1 3511/4885TSHR 386/4885SMN1; SMN2 4802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.